- Prophylaxis in kidney transplant rejection in patients with low-moderate immunologic risk:
- PO 0.75mg BD initially
- May adjust dose every 4-5 days based on trough levels
- Adjust maintenance dose to achieve trough whole blood concentrations of 3-8 ng/mL target range
- Use in combination with reduced doses of cyclosporine, basiliximab and corticosteroids
- Prophylaxis of allograft rejection in adult liver transplant recipients:
- PO 1mg BD initially, started 30 days after transplant
- Adjust maintenance dose to achieve trough whole blood concentrations of 3-5 ng/mL by 3 weeks after first dose of everolimus and through 12 months
- If 2 consecutive trough level >8ng/mL decrease dose by 0.5mg/day
- Use in combination with reduced doses of tacrolimus and with corticosteroids
- Tablet:
- 0.25mg
- 0.5mg
- 0.75mg
- 1mg
Administered consistently with food or consistently without food
Immunosuppressant
It inhibits mammalian target of rapamycin (mTOR) kinase activity, inhibiting T and B lymphocyte activation and proliferation
- Peripheral edema
- Constipation
- Hypertension
- Nausea
- Anemia
- UTI
- Hyperlipidemia
- Diarrhea
- Fever
- Elevated creatine
- Hyperkalemia
- Headache
- Insomnia
- URI
- Procedural pain
- Vomiting
- Hypomagnesemia
- Abdominal pain
- Hypophosphatemia
- Hyperglycemia
- Hypokalemia
- Extremity pain
- Hematuria
- Back pain
- Dysuria
- Fatigue
- Stomatitis
- Tremor
- Cough
- Dyspepsia
- Leukopenia
- Proteinuria
- Hypersensitivity to class/components
- Hypersensitivity to sirolimus
- Heart transplant use
- Galactose intolerance
- Lapp lactase deficiency
- Glucose malabsorption
- Galactose malabsorption
WARNING
- Co-administration with standard doses of cyclosporine may increase nephrotoxicity therefore important to reduce cyclosporine dose
- Increase thrombosis risk resulting in graft loss has been reported mostly within 30 days post-transplant
- Increased mortality, often associated with serious infections, reported within the first 3 months post-transplantation when used with heart transplants
- Used ONLY with medical personnel experienced in immunosuppression treatment and management of transplant patients in adequate medical facility
- Live bacterial vaccines
- Cidofovir
- Cisapride
- Ritonavir
- Tamoligene
Drug Status
| Availability | Prescription only |
| Pregnancy | Category C |
| Breastfeeding | Contraindicated |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Certican | 0.25mg | Tablet | 60’s | Novartis Pharma | Novartis Kenya |
| Certican | 0.5mg | Tablet | 60’s | Novartis Pharma | Novartis Kenya |
| Certican | 0.75mg | Tablet | 60’s | Novartis Pharma | Novartis Kenya |
| Certican | 1mg | Tablet | 60’s | Novartis Pharma | Novartis Kenya |
| Everbliss | 10mg | Tablet | 10’s | BDR Pharma | Ripple Pharma |